Veterinary Immunology and Immunopathology is a premier journal published by Elsevier, dedicated to advancing the field of veterinary science through rigorous investigations into the immunological mechanisms that underpin disease resistance, pathogenesis, and therapeutic interventions in animals. With an established history since 1979, this journal has consistently provided a platform for high-quality research, bridging the gap between immunology and veterinary medicine. The current impact factor reflects its significance within the field, particularly noted for its Q3 ranking in Immunology and Q2 in miscellaneous Veterinary categories as of 2023. The journal caters to a diverse audience, from seasoned researchers to students, by publishing original research, reviews, and case studies that explore pivotal topics such as vaccine development, immune response in various species, and the role of genetics in immunological disorders. Notably, it is indexed in Scopus, where it ranks in the top percentile of veterinary science disciplines, enhancing its visibility and impact within the scientific community. For those seeking to stay at the forefront of veterinary immunology, this journal is an invaluable resource.

INFECTION is a prestigious journal, published by Springer Heidelberg, that serves as a leading platform for the dissemination of critical research in the fields of Infectious Diseases, Microbiology, and Medicine. With an impressive Q1 ranking in multiple categories such as Infectious Diseases, Medicine (miscellaneous), and Medical Microbiology, the journal is recognized for its high-quality content and impactful contributions to the scientific community, as evidenced by its Scopus rankings placing it in the top 10th percentiles. Since its inception in 1973, and projected to continue until 2024, INFECTION has established itself as a vital resource for researchers, healthcare professionals, and students keen to explore the latest findings and advancements in infectious diseases. The journal provides a rigorous peer-review process, ensuring that only high-quality studies are published, making it an essential read for those seeking to deepen their understanding and stay abreast of the rapidly evolving landscape in infection research.

npj Vaccines, published by NATURE PORTFOLIO, is an esteemed Open Access journal that has been at the forefront of vaccination research since its inception in 2016. With an impressive impact factor and ranking in the top quartile (Q1) across several categories including Immunology, Infectious Diseases, and Pharmacology, this journal provides a crucial platform for the dissemination of high-quality research and innovative findings in the field of vaccine development. Based in the United Kingdom, and with its broad scope encompassing both fundamental and translational studies, npj Vaccines facilitates significant discourse among researchers, professionals, and students dedicated to immunization strategies and public health. The journal's commitment to Open Access ensures that vital knowledge is shared widely, promoting collaboration and advancement in vaccine science on a global scale. Scholars are encouraged to contribute to this essential field, as their findings may significantly impact the future of disease prevention and control.

Minerva Biotechnology and Biomolecular Research is an emerging journal published by EDIZIONI MINERVA MEDICA, dedicated to the fields of biotechnology, biomolecular research, and applied microbiology. With an ISSN of 2724-542X and an E-ISSN of 2724-5934, this journal aims to foster deeper understanding and innovative advancements in these rapidly evolving disciplines. The journal has been categorized in the Q4 quartile across four categories in the 2023 rankings, highlighting its nascent yet growing influence within the scientific community. Operating on an open-access model, it enhances accessibility and encourages the dissemination of knowledge to researchers, professionals, and students alike. Set in the heart of Italy, specifically at CORSO BRAMANTE 83-85 INT JOURNALS DEPT., 10126 TURIN, ITALY, Minerva Biotechnology and Biomolecular Research will continue to enrich the scientific literature from its inception in 2021 through 2024 and beyond, contributing to the global dialogue on biotechnological innovations and molecular research.

Tuberculosis is an esteemed peer-reviewed journal specializing in the fields of Infectious Diseases, Immunology, and Microbiology, published by Churchill Livingstone since 1974. With a scope aimed at advancing the understanding and management of tuberculosis and related infectious diseases, the journal provides a platform for innovative research findings, clinical practices, and policy discussions. It is ranked in the Q2 category for both Infectious Diseases and Microbiology (medical), reflecting its significance in the academic community and the impact of its published work. The journal's commitment to openness is evident in its access options, fostering wider dissemination of knowledge. With an impact factor that underscores its relevance, Tuberculosis serves as a crucial resource for researchers, healthcare professionals, and students dedicated to combatting these pressing health challenges. The journal operates from its production headquarters in Edinburgh, Scotland, ensuring a strong connection to the international research community.

INTERNATIONAL REVIEWS OF IMMUNOLOGY, published by Taylor & Francis Inc, is a leading academic journal that has been a cornerstone of immunological research since its inception in 1986. With an impressive impact factor and ranked in the top quartiles of its field (Q2 in both Immunology and Allergy), this journal offers a critical platform for the dissemination of influential findings and advancements within immunology. Spanning a diverse array of topics, from basic immune mechanisms to clinical applications, it aims to support the global scientific community in enhancing immunological understanding and therapeutic interventions. Researchers and professionals alike benefit from insights provided by renowned contributors, ensuring that the journal remains relevant in a rapidly evolving field. Directly accessible through subscription or institutional access, INTERNATIONAL REVIEWS OF IMMUNOLOGY is committed to fostering collaboration and innovation, making it an essential resource for anyone involved in immunological research and practice.

DRUG DEVELOPMENT RESEARCH is a premier interdisciplinary journal published by Wiley, focusing on the latest advancements in drug discovery, pharmacology, and toxicology. With an ISSN of 0272-4391 and an E-ISSN of 1098-2299, this esteemed publication has been a cornerstone in the field since its inception in 1981 and continues to provide cutting-edge research until 2024. Its rigorous peer-review process and strategic placement in Q2 of the Drug Discovery category, as well as ranking #60 out of 157 in Scopus, underscore the journal's relevance and influence, boasting a respectable 62nd percentile ranking. While the journal does not currently offer open access, it remains a vital resource for researchers, professionals, and students seeking to expand their knowledge on the processes of drug development, identifying new therapeutic targets, and assessing the efficacy and safety of novel compounds. Situated in Hoboken, NJ, this journal stands at the forefront of pharmaceutical innovation, making significant contributions to the advancement of medical science.

MICROBIOLOGY AND IMMUNOLOGY, an esteemed journal published by WILEY, serves as a vital resource for researchers and professionals in the fields of microbiology, immunology, and virology. With its ISSN 0385-5600 and E-ISSN 1348-0421, this journal has been a cornerstone in scientific literature since its inception in 1977, bridging decades of research and innovation through its comprehensive coverage of emerging trends and discoveries. Although this journal operates without open access, it maintains a commendable presence in academic circles, reflected in its 2023 Quartile rankings of Q3 across the categories of Immunology, Microbiology, and Virology. As part of an important discourse in these disciplines, MICROBIOLOGY AND IMMUNOLOGY ensures its scholarly contributions are relevant to both seasoned researchers and emerging scholars. Positioned in a competitive journal landscape, with Scopus ranks indicating a median percentile across its fields, it remains committed to advancing knowledge through peer-reviewed articles, thereby supporting the continuous evolution of its focus areas. The journal's current scope encompasses topics critical for understanding pathogen-host interactions and the immune response, making it a crucial publication for any academic library or individual scholar dedicated to the biological sciences.

Vaccine: X, published by Elsevier, is a premier open access journal dedicated to advancing research in the interdisciplinary fields of immunology and microbiology, infectious diseases, molecular medicine, and public health. With an ISSN of 2590-1362 and operating since 2019, the journal has rapidly established an influential role, achieving Q2 rankings in major categories such as Immunology and Microbiology, Infectious Diseases, and Public Health for 2023. Its commitment to disseminating cutting-edge research is evident from its broad scope, focusing on innovative vaccines and therapies that are critical for global health. Researchers and professionals will find value in the accessible nature of the journal, which has been recognized for its contributions to veterinary medicine as well, with a Q1 ranking in the miscellaneous veterinary category. The journal proudly showcases high-quality, peer-reviewed articles and welcomes submissions that push the boundaries of current knowledge, making it an essential resource for anyone involved in vaccine research and development.

The JOURNAL OF INFECTIOUS DISEASES, published by OXFORD UNIV PRESS INC, is a leading peer-reviewed journal dedicated to advancing the understanding of infectious diseases through high-quality research. With an impressive impact factor reflecting its prominence in the field—ranking in the Q1 category for both Immunology and Allergy and Infectious Diseases—this journal serves as a pivotal platform for researchers, healthcare professionals, and students alike. Its extensive history, spanning over a century since its inception in 1904, highlights its established authority and commitment to the field. Based in the United Kingdom, the journal covers essential topics from clinical management to epidemiological trends, providing vital insights that inform practice and policy. Although the journal is not open access, it remains accessible to a wide audience, ensuring that critical research continues to drive innovation and best practices in infectious disease management.